Key facts
- This page summarizes Wei Jiang's Form 4 filing for STAAR SURGICAL CO (STAA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2024, 17:02.
Wei Jiang - 20 Jun 2024 Form 4 Insider Report for STAAR SURGICAL CO (STAA)
- Reporting relationship
- Director
- Issuer ticker
- STAA
- Reported as of
- 20 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2024, 17:02:57 UTC
- Prior SEC filing
- 01 Apr 2024
- Next SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nathaniel Sisitsky as attorney-in-fact for Wei Jiang
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Wei Jiang filed Form 4 for STAAR SURGICAL CO (STAA) on 24 Jun 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STAA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,244
- Change %
- +173%
- Price
- $0.000000
- Shares after
- 3,543
- Date
- 20 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
STAA
transaction
Derivative
Common Stock Options
Award
- Transaction value
- $0
- Shares
- +4,010
- Change %
- Price
- $0.000000
- Shares after
- 4,010
- Date
- 20 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,010
- Exercise price
- $40.11
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects shares of restricted stock and options to purchase common stock granted on June 20, 2024, pursuant to the Corporation's annual non-employee director equity compensation program for the 2024-2025 term. These equity awards vest in full on the earlier of June 20, 2025, or the Corporation's 2025 Annual Meeting of Shareholders.